Detalhe da pesquisa
1.
MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway.
J Thorac Dis
; 10(Suppl 17): S2076-S2078, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30023123